BR0009947A - Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano - Google Patents

Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano

Info

Publication number
BR0009947A
BR0009947A BR0009947-3A BR0009947A BR0009947A BR 0009947 A BR0009947 A BR 0009947A BR 0009947 A BR0009947 A BR 0009947A BR 0009947 A BR0009947 A BR 0009947A
Authority
BR
Brazil
Prior art keywords
antimicrobial
conjugate
antimicrobial conjugate
medical device
viable microorganisms
Prior art date
Application number
BR0009947-3A
Other languages
English (en)
Inventor
Wenda C Carlyle
Original Assignee
St Jude Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Medical filed Critical St Jude Medical
Publication of BR0009947A publication Critical patent/BR0009947A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"CONJUGADO ANTIMICROBIANO, MéTODO DE ELIMINAR MICROORGANISMOS VIáVEIS, DISPOSITIVO MéDICO, E, MéTODO DE FORMAR UM CONJUGADO ANTIMICROBIANO". Um conjugado antimicrobiano (100, 120, 154) pode ser formado de modo que inclua um anticorpo (100, 122) ou um ligante ligado a um agente antimicrobiano (106, 124). O anticorpo (102, 122, 154) ou o ligante têm uma afinidade aos antígenos ou receptores microbianos. O conjugado antimicrobiano (100, 120, 154) pode ser usado sozinho ou associado com material biocompatível (152) incorporados em um dispositivo médico (150). Um conjugado antimicrobiano (100, 120, 154) pode ser colocado em contato com uma solução para eliminar microorganismos viáveis da solução. Em particular, o conjugado antimicrobiano (100, 120, 154) pode ser usado para reduzir o risco de infecção associada com o contato de um dispositivo médico com os fluidos ou tecidos corpóreos do paciente.
BR0009947-3A 1999-04-23 2000-03-30 Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano BR0009947A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29863899A 1999-04-23 1999-04-23
PCT/US2000/008389 WO2000064487A2 (en) 1999-04-23 2000-03-30 Delivery of antimicrobial toxins

Publications (1)

Publication Number Publication Date
BR0009947A true BR0009947A (pt) 2002-12-31

Family

ID=23151378

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009947-3A BR0009947A (pt) 1999-04-23 2000-03-30 Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano

Country Status (5)

Country Link
EP (1) EP1212094A2 (pt)
JP (1) JP2003523315A (pt)
BR (1) BR0009947A (pt)
WO (1) WO2000064487A2 (pt)
ZA (1) ZA200108639B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019309T2 (de) * 1999-09-16 2005-09-22 Unilever Plc Abgabesystem für ein mittel gegen schuppen
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
DE10245434B4 (de) * 2002-09-27 2006-03-16 Micronas Holding Gmbh Verfahren und Vorrichtung zur Bestimmung der Konzentration von in einer flüssigen Probe enthaltenen Liganden
AU2013226216B2 (en) 2012-02-27 2016-04-07 Beech Tree Labs, Inc. Method of treating chronic obstructive pulmonary disease
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
WO2021203024A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof

Also Published As

Publication number Publication date
ZA200108639B (en) 2003-07-30
WO2000064487A8 (en) 2002-01-31
EP1212094A2 (en) 2002-06-12
JP2003523315A (ja) 2003-08-05
WO2000064487A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
Moyer et al. Treatment of large human burns with 0.5% silver nitrate solution
IL133265A0 (en) Heparanase specific molecular probes and their use in research and medical applications
HUP0001647A2 (hu) Abszorbens cikkek bőrtejjel kezelt combmandzsettákkal
ATE353678T1 (de) Beschichtung für medizinische geräte
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR9807916A (pt) Conjunto de dispositivo biomédico, método para inibir substancialmente a reestenose em um vaso sanguìneo de um paciente, método para fabricar um conjunto de dispositivo biomédico.
DE3267907D1 (en) Absorbent composition for blood and serous body fluids
BR9814836A (pt) "material de textura, textura de material extensìvel e artigo absorvente"
TW224428B (pt)
DE59510781D1 (de) In den Körper eines Patienten perkutan implantierbare Endoprothese
WO2003035142A3 (en) Catheter for modified perfusion
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
ATE307625T1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
ATE197549T1 (de) Methoden zur regulation der den magen und darm betreffenden motilitaet
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
BR0009947A (pt) Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano
AR023271A1 (es) Conjugado polimerico capaz de inhibir una o mas enzimas proteoliticas
WO2021086855A1 (en) Urinary catheters and methods for preventing bacterial infections
Diranzo García et al. Skin abscess due to Serratia marcescens in an immunocompetent patient after receiving a tattoo
Meleney et al. The Combined Use of Zinc Peroxide and Sulfanilamide in the Treatment of Chronic, Undermining, Burrowing Ulcers Due to the Micro-Aerophilic Hemolytic Streptococcus
WO1996032134A3 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
Hoffstedt et al. Penetration of ceftazidime into extracellular fluid in patients
WO2022096671A1 (de) Schutzvorrichtung als temporäre versiegelung während sexueller aktivitäten zur vermeidung von harnwegs- und blasenentzündungen
GB0114672D0 (en) Pharmaceutical formulations and methods of medical treatment
Langefeld et al. Use of lavage fluid containing diphoterine for irrigation of eyes in first aid emergency treatment

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61L 29/16 (2006.01), A61K 47/68 (2017.01), A61K 4